Product

Details:​

A synthetic 39-amino-acid peptide that acts as a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Formulated with a C20 fatty diacid moiety that binds to albumin to enable a prolonged ~5-day half-life, it synergistically harnesses both incretin pathways to optimize glucose homeostasis, delay gastric emptying, suppress appetite centrally in the hypothalamus, and enhance insulin sensitivity and lipid metabolism.

​

Key Benefits:

• Superior Weight Loss & Adiposity Reduction: Clinically demonstrated average body weight reductions of 20% to 22.5%+ at maintenance doses (10 mg–15 mg), outperforming selective single-target GLP-1 receptor agonists.

• Dual Incretin Synergy: Combines GLP-1's appetite suppression and slowed gastric transit with GIP receptor agonism, which enhances insulin sensitivity, buffers postprandial lipid surges, and improves gastrointestinal tolerability.

• Robust Glycemic & HbA1c Control: Dramatically lowers fasting blood glucose and postprandial spikes while bringing HbA1c down to non-diabetic ranges in the vast majority of trial subjects.

• Cardiometabolic & Hepatic Improvements: Drives meaningful reductions in circulating triglycerides, LDL cholesterol, and systolic blood pressure, while substantially reducing intrahepatic fat content.

• Suppression of Central Food Noise: Acts directly on hypothalamic feeding circuits to quell compulsive cravings, reward-driven eating patterns, and appetite.

​

Ideal For:

• Medical weight management and obesity treatment, particularly for individuals seeking substantial, clinically proven fat loss approaching surgical benchmarks.

• Patients plateaued on single-agonist GLP-1 therapies (such as semaglutide) requiring greater metabolic potency and deeper satiety signaling.

• Type 2 Diabetes and severe insulin resistance, especially when accompanied by central visceral adiposity and elevated cardiovascular risk markers.

• Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) seeking significant reductions in visceral and hepatic lipid accumulation.